Celgene Corp. buy matumba
Start price
22.10.11
/
50%
€24.05
Target price
28.12.11
€26.08
Performance (%)
8.41%
End price
28.12.11
€26.08
Summary
This prediction ended on 28.12.11 with a price of €26.08. With a performance of 8.41%, the BUY prediction by matumba for Celgene Corp. closed with a slight gain. matumba has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | -1.933% | 2.239% | 16.921% | 61.658% |
| iShares Nasdaq 100 | -0.972% | 0.226% | 5.003% | 104.644% |
| iShares Nikkei 225® | -2.056% | 5.685% | 19.218% | 51.355% |
| iShares S&P 500 | -1.185% | 0.867% | 2.378% | 66.527% |
Comments by matumba for this prediction
In the thread Celgene Corp. diskutieren
risikobereit?
Revlimid Präparat gegen Krebs soll 2012 ein Umsatzplus von 30% bringen (3,15MRD Dollar)
Europ. Arzneimittelagentur hat sich positiv geäußert- dies ermögl. gute Chancen
(Zielkurs erreicht)


